

Michael Rink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/192975/publications.pdf>

Version: 2024-02-01

174
papers

5,084
citations

117625

34
h-index

114465

63
g-index

178
all docs

178
docs citations

178
times ranked

4741
citing authors

#	ARTICLE	IF	CITATIONS
1	Anesthetic Technique (Spinal vs. General Anesthesia) in Holmium Laser Enucleation of the Prostate: Retrospective Analysis of Procedural and Functional Outcomes among 1,159 Patients. <i>Urologia Internationalis</i> , 2023, 107, 336-343.	1.3	2
2	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	2.5	16
3	Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 457-464.	3.1	14
4	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	4.2	6
5	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	2.7	6
6	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2022, 61, 52-57.	1.8	0
7	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 1489-1496.	2.2	3
8	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. <i>World Journal of Urology</i> , 2022, 40, 1167-1174.	2.2	9
9	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	1.6	8
10	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology "Young Academic Urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 195.e27-195.e35.	1.6	5
11	Urinary Diversion With or Without Concomitant Cystectomy for Benign Conditions: A Comparative Morbidity Assessment According to the Updated European Association of Urology Guidelines on Reporting and Grading of Complications. <i>European Urology Focus</i> , 2022, 8, 1831-1839.	3.1	6
12	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. <i>Cancers</i> , 2022, 14, 1781.	3.7	1
13	Re: Christopher Soliman, Niranjana J. Sathianathan, Gianluca Giannarini, et al. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2021.12.022 , <i>European Urology</i> , 2022, 81, e150-e150.	1.9	0
14	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	3.1	10
15	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	1.0	2
16	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	2.2	20
17	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. <i>World Journal of Urology</i> , 2021, 39, 1947-1953.	2.2	7
18	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 580-593.	5.4	19

#	ARTICLE	IF	CITATIONS
19	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	2.2	11
20	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World Journal of Urology, 2021, 39, 443-451.	2.2	13
21	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World Journal of Urology, 2021, 39, 829-837.	2.2	3
22	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	1.6	9
23	Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases. Journal of Endourology, 2021, 35, 639-646.	2.1	20
24	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	1.6	8
25	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	2.2	18
26	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	6.8	33
27	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish Journal of Urology, 2021, 47, S33-S44.	1.3	1
28	Y-chromosome loss is frequent in male renal tumors. Annals of Translational Medicine, 2021, 9, 209-209.	1.7	13
29	Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World Journal of Urology, 2021, 39, 2977-2985.	2.2	6
30	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	1.4	3
31	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	1.9	12
32	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naïve clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	1.4	11
33	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly – An International Multicenter Study. Bladder Cancer, 2021, 7, 173-185.	0.4	0
34	A Systematic Review and Scoping Analysis of Smoking Cessation after a Urological Cancer Diagnosis. Journal of Urology, 2021, 205, 1275-1285.	0.4	6
35	Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. Current Opinion in Urology, 2021, 31, 291-296.	1.8	8
36	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. Future Oncology, 2021, 17, 2325-2338.	2.4	3

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.4	5
38	Fighting the “tobacco epidemic” – A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 793-796.	1.6	2
39	Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS). <i>Frontiers in Oncology</i> , 2021, 11, 759362.	2.8	7
40	Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. <i>Frontiers in Surgery</i> , 2021, 8, 763271.	1.4	3
41	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	8
42	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. <i>European Urology Focus</i> , 2020, 6, 1226-1232.	3.1	18
43	Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2020, 38, 1165-1175.	2.2	72
44	Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. <i>European Urology</i> , 2020, 77, 55-65.	1.9	85
45	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020, 38, 1959-1968.	2.2	22
46	Reply to Liang Sun and Yi Feng’s Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. <i>Eur Urol</i> 2019;77:55–65. <i>European Urology</i> , 2020, 77, e12-e13.	1.9	2
47	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 43.e13-43.e20.	1.6	8
48	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
49	Pathomics in urology. <i>Current Opinion in Urology</i> , 2020, 30, 823-831.	1.8	10
50	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	1.6	7
51	Pathogen-induced tissue-resident memory T _H 17 (T _{RM} 17) cells amplify autoimmune kidney disease. <i>Science Immunology</i> , 2020, 5, .	11.9	58
52	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer – examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.	1.6	6
53	Prevalence of APC and PTEN Alterations in Urachal Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 2773-2781.	1.9	10
54	Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP) – Impact on sexual function and evaluation of patient bother using validated questionnaires. <i>Andrology</i> , 2020, 8, 1779-1786.	3.5	13

#	ARTICLE	IF	CITATIONS
55	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. <i>European Urology Open Science</i> , 2020, 22, 45-50.	0.4	6
56	Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. <i>Scientific Reports</i> , 2020, 10, 21562.	3.3	6
57	The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3478.	2.4	5
58	Learning benefits of live surgery and semi-live surgery in urologyâ€”informing the debate with results from the International Meeting of Reconstructive Urology (IMORU) VIII. <i>World Journal of Urology</i> , 2020, 39, 2801-2807.	2.2	3
59	Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchiaâ€™s Letter to the Editor re: Maite W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. <i>Eur Urol</i> 2020;77:55â€“65. <i>European Urology</i> , 2020, 78, e77-e78.	1.9	0
60	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). <i>Oncoimmunology</i> , 2020, 9, 1738798.	4.6	34
61	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 128.	1.9	3
62	The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 739.e9-739.e15.	1.6	11
63	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 605.e1-605.e8.	1.6	3
64	Longitudinal Evaluation of Perineogenital Pain and Postoperative Complications After One-stage Buccal Mucosal Graft Urethroplasty: A Secondary Analysis of a Randomized Controlled Trial. <i>European Urology Focus</i> , 2020, 7, 1157-1165.	3.1	3
65	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. <i>Oncotarget</i> , 2020, 11, 237-249.	1.8	19
66	Why is the principle of â€œas much radicality as needed, as much organ preservation as possibleâ€•only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients?. <i>Translational Andrology and Urology</i> , 2020, 9, 1901-1903.	1.4	2
67	Electronic cigarettes and bladder cancer â€” a game-changer?. <i>Nature Reviews Urology</i> , 2020, 17, 435-436.	3.8	0
68	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 685.e17-685.e25.	1.6	2
69	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: Analysis of the STAR TOR registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 628-628.	1.6	1
70	CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS770-TPS770.	1.6	0
71	Effect of comorbidities/comedications on treatment outcomes with sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Subgroup analyses from the STAR-TOR registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 631-631.	1.6	0
72	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1192.	2.4	13

#	ARTICLE	IF	CITATIONS
73	Current Disease Management of Primary Urethral Carcinoma. <i>European Urology Focus</i> , 2019, 5, 722-734.	3.1	34
74	Negative Self-Perception and Self-Attitude of Sexuality Is a Risk Factor for Patient Dissatisfaction Following Penile Surgery with Small Intestinal Submucosa Grafting for the Treatment of Severe Peyronie's Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1121.	2.4	10
75	Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1459.	2.4	12
76	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. <i>Surgical Oncology</i> , 2019, 28, 208-213.	1.6	14
77	Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e522-e525.	1.9	1
78	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in perioperative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	2.5	53
79	Outcome of buccal mucosa graft urethroplasty: a detailed analysis of success, morbidity and quality of life in a contemporary patient cohort at a referral center. <i>BMC Urology</i> , 2019, 19, 18.	1.4	15
80	The current role of circulating biomarkers in non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 61-75.	1.4	11
81	Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e19-179.e28.	1.6	25
82	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e1-179.e7.	1.6	8
83	The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. <i>World Journal of Urology</i> , 2019, 37, 1785-1799.	2.2	18
84	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. <i>European Urology Focus</i> , 2019, 5, 681-688.	3.1	48
85	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. <i>World Journal of Urology</i> , 2018, 36, 1067-1072.	2.2	18
86	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e19-238.e27.	1.6	3
87	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018, 4, 252-259.	3.1	18
88	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 10.e7-10.e14.	1.6	12
89	Immunotherapy for metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 1-7.	1.8	6
90	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology's Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	2.5	61

#	ARTICLE	IF	CITATIONS
91	Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity. <i>European Urology</i> , 2018, 73, 910-922.	1.9	31
92	Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation. <i>Urologia Internationalis</i> , 2018, 101, 285-292.	1.3	4
93	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 531.e19-531.e25.	1.6	17
94	Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1123-e1132.	1.9	19
95	Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA. <i>Journal of Clinical Oncology</i> , 2018, 36, 495-495.	1.6	1
96	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. <i>BJU International</i> , 2017, 119, 234-238.	2.5	16
97	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2017, 35, 113-120.	2.2	22
98	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	2.2	37
99	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 558-558.	0.4	0
100	β ² III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. <i>Human Pathology</i> , 2017, 61, 210-220.	2.0	23
101	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	2.2	29
102	Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. <i>BJU International</i> , 2017, 119, 854-861.	2.5	27
103	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e809-e817.	1.9	21
104	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 356-362.	1.6	4
105	The effect of ABO and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 671.e17-671.e23.	1.6	1
106	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1039-e1045.	1.9	14
107	A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 381-389.	5.1	33
108	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 379-387.	2.2	260

#	ARTICLE	IF	CITATIONS
109	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. <i>Bladder Cancer</i> , 2017, 3, 161-169.	0.4	12
110	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. <i>Oncotarget</i> , 2017, 8, 56398-56407.	1.8	25
111	The landscape of genetics and biomarkers in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1027-1030.	1.4	4
112	The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1090-1110.	1.4	22
113	Online tools for patient counseling in bladder and kidney cancer—ready for prime time?. <i>Translational Andrology and Urology</i> , 2017, 6, 1123-1131.	1.4	2
114	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. <i>Translational Andrology and Urology</i> , 2017, 6, 1018-1026.	1.4	12
115	Liquid biopsies in bladder cancer—did we find the Holy Grail for biomarker analyses?. <i>Translational Andrology and Urology</i> , 2016, 5, 980-983.	1.4	8
116	Female with bladder cancer: what and why is there a difference?. <i>Translational Andrology and Urology</i> , 2016, 5, 668-682.	1.4	52
117	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , 2016, 118, 243-249.	2.5	14
118	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 483.e17-483.e24.	1.6	54
119	Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 432.e1-432.e8.	1.6	8
120	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016, 2, 79-85.	3.1	39
121	Re: Vinflunine in Routine Clinical Practice for the Treatment of Advanced or Metastatic Urothelial Cell Carcinoma—Data from a Prospective, Multicenter Experience. <i>European Urology</i> , 2016, 69, 373-374.	1.9	0
122	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. <i>World Journal of Urology</i> , 2016, 34, 97-103.	2.2	51
123	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e1-233.e6.	1.6	22
124	Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 96-104.	1.9	14
125	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2016, 34, 1411-1419.	2.2	10
126	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016, 34, 1155-1161.	2.2	4

#	ARTICLE	IF	CITATIONS
127	Psychometric validation of a German language version of a PROM for urethral stricture surgery and preliminary testing of supplementary ED and UI constructs. World Journal of Urology, 2016, 34, 369-375.	2.2	30
128	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature. Journal of Urology, 2016, 195, 254-263.	0.4	99
129	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. European Urology Focus, 2015, 1, 17-27.	3.1	80
130	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. Journal of Urology, 2015, 194, 1456-1462.	0.4	25
131	Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder. World Journal of Urology, 2015, 33, 1753-1761.	2.2	28
132	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World Journal of Urology, 2015, 33, 1419-1428.	2.2	19
133	βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 1561-1569.	2.2	14
134	The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Urology, 2015, 86, 92-98.	1.0	26
135	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. European Urology, 2015, 68, 949-956.	1.9	50
136	The impact of the ABO and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World Journal of Urology, 2015, 33, 1769-1776.	2.2	13
137	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	1.6	15
138	Do Circulating Tumor Cells Have a Role in Deciding on Adjuvant Chemotherapy After Radical Cystectomy?. Current Urology Reports, 2015, 16, 46.	2.2	14
139	Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e1-21.e9.	1.6	48
140	Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.. Journal of Clinical Oncology, 2015, 33, 4568-4568.	1.6	1
141	Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. Canadian Urological Association Journal, 2014, 8, 75.	0.6	11
142	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 433-440.	1.6	31
143	Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. European Urology, 2014, 65, 742-754.	1.9	159
144	Histopathological Characteristics of Buccal Mucosa Transplants in Humans after Engraftment to the Urethra: A Prospective Study. Journal of Urology, 2014, 192, 1725-1729.	0.4	28

#	ARTICLE	IF	CITATIONS
145	Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy. <i>European Journal of Cancer</i> , 2014, 50, 2583-2591.	2.8	19
146	Reduced membranous MET expression is linked to bladder cancer progression. <i>Cancer Genetics</i> , 2014, 207, 147-152.	0.4	5
147	Re: Global Effects of Smoking, of Quitting, and of Taxing Tobacco. <i>European Urology</i> , 2014, 66, 176-178.	1.9	4
148	Impact of Preoperative Anemia on Oncologic Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2014, 191, 316-322.	0.4	49
149	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	1.9	201
150	Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4587-4587.	1.6	1
151	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , 2013, 111, 74-84.	2.5	26
152	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. <i>International Urology and Nephrology</i> , 2013, 45, 1561-1567.	1.4	13
153	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, E30-6.	2.5	77
154	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. <i>Journal of Urology</i> , 2013, 189, 1214-1221.	0.4	291
155	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. <i>European Urology</i> , 2013, 63, 1082-1090.	1.9	98
156	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1716-1724.	1.6	15
157	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	2.8	154
158	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	1.9	101
159	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	1.9	61
160	Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 724-732.	1.9	105
161	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , 2013, 112, 623-637.	2.5	31
162	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	2.5	128

#	ARTICLE	IF	CITATIONS
163	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World Journal of Urology, 2012, 30, 807-814.	2.2	16
164	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. European Urology, 2012, 62, 677-684.	1.9	93
165	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Annals of Surgical Oncology, 2012, 19, 4337-4344.	1.5	53
166	Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2012, 188, 398-404.	0.4	114
167	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. Current Urology Reports, 2012, 13, 122-135.	2.2	51
168	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. European Urology, 2012, 61, 854-855.	1.9	152
169	Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study. European Urology, 2012, 61, 810-817.	1.9	163
170	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2012, 30, 281-281.	1.6	0
171	Detection of circulating tumour cells in peripheral blood of patients with advanced nonâ€metastatic bladder cancer. BJU International, 2011, 107, 1668-1675.	2.5	89
172	Older patients suffer from adverse histopathological features after radical cystectomy. International Journal of Urology, 2011, 18, 576-584.	1.0	15
173	Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thrombosis and Haemostasis, 2009, 101, 1147-1155.	3.4	67
174	Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thrombosis and Haemostasis, 2009, 101, 1147-55.	3.4	25